CC
BMRN icon

Carlson Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Carlson Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-228
Closed -$251K – 287
2015
Q4 		$251K Sell
228
-156
-41% -$16.3K ﹤0.01% 295
2015
Q3 		$817K Buy
+384
New +$51.3K 0.01% 274

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Carlson Capital's BMRN Position: Q2 2017 in Review

Carlson Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2017, closing a stake of 400,572 shares — an estimated $35.2M sold.

Carlson Capital first reported a position in BMRN in Q1 2016 and held it in 3 quarters. The position peaked at $53M in Q4 2016. 426 funds tracked by Wall St. Rank hold BMRN as of Q2 2017.

  • Carlson Capital reported no remaining BioMarin Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Carlson Capital sold 400,572 BioMarin Pharmaceuticals shares in Q2 2017, an estimated $35.2M.
  • Carlson Capital first reported a position in BioMarin Pharmaceuticals in Q1 2016 and held it in 3 quarters.
  • Carlson Capital's BioMarin Pharmaceuticals position peaked at $53M in Q4 2016.
  • 426 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2017.

Based on Carlson Capital's 13F filing for Q2 2017, filed 14 Aug 2017.